Table 1 Clinical characteristics of patients with localized SN-DLBCL and SN-ENKTL
Characteristic | All patients (nā=ā258), n (%) | SN-DLBCL (nā=ā47), n (%) | SN-ENKTL (nā=ā211), n (%) | p(SN-DLBCL vs. SN-ENKTL) |
|---|---|---|---|---|
Sex | ||||
āMale | 174 (67.4) | 25 (53.2) | 149 (70.6) | 0.021 |
āFemale | 84 (32.6) | 22 (46.8) | 62 (29.4) | |
Age (year) | ||||
āMedian (range) | 43 (10ā85) | 63 (11ā82) | 40 (10ā85) | <0.001 |
āā¤60 | 225 (87.2) | 25 (53.2) | 200 (94.8) | |
ā>60 | 33 (12.8) | 22 (46.8) | 11 (5.2) | |
Modified Ann Arbor stage | ||||
āLimited I | 73 (28.3) | 3 (6.4) | 70 (33.2) | 0.001 |
āExtensive I | 126 (48.8) | 32 (68.1) | 94 (44.5) | |
āII | 59 (22.9) | 12 (25.5) | 47 (22.3) | |
Nodal involvement | ||||
āPresent | 49 (19.0) | 10 (21.3) | 39 (18.5) | 0.659 |
āAbsent | 209 (81.0) | 37 (78.7) | 172 (81.5) | |
B symptoms | ||||
āPresent | 104 (40.3) | 5 (10.6) | 99 (46.9) | <0.001 |
āAbsent | 154 (59.7) | 42 (89.4) | 112 (53.1) | |
LDH level | ||||
āNormal | 192 (74.4) | 37 (78.7) | 155 (73.5) | 0.514 |
āElevated | 64 (24.8) | 10 (21.3) | 54 (25.6) | |
āUnknown | 2 (0.8) | 0 (0.0) | 2 (0.9) | |
ECOG performance status | ||||
ā0 | 141 (54.7) | 25 (53.2) | 116 (55.0) | 0.018 |
ā1 | 94 (36.4) | 13 (27.7) | 81 (38.4) | |
āā„2 | 23 (8.9) | 9 (19.1) | 14 (6.6) | |
mIPI | ||||
ā0 | 126 (48.8) | 13 (27.7) | 113 (53.6) | 0.001 |
ā1 | 92 (35.7) | 20 (42.5) | 72 (34.1) | |
ā2ā4 | 38 (14.7) | 14 (29.8) | 24 (11.4) | |
āUnknown | 2 (0.8) | 0 (0.0) | 2 (0.9) | |
Treatment strategy | ||||
āCMT | 147 (57.0) | 37 (78.7) | 110 (52.1) | <0.001 |
āChemotherapy alone | 17 (6.6) | 10 (21.3) | 7 (3.3) | |
āRadiotherapy alone | 94 (36.4) | 0 (0.0) | 94 (44.6) | |
Response to treatment | ||||
āCR/CRu | 205 (79.5) | 36 (76.6) | 169 (80.1) | 0.686 |
āPR | 23 (8.9) | 6 (12.7) | 17 (8.1) | |
āSD | 1 (0.4) | 0 (0.0) | 1 (0.5) | |
āPD | 15 (5.8) | 2 (4.3) | 13 (6.2) | |
āNot evaluable | 14 (5.4) | 3 (6.4) | 11 (5.1) | |